Lupin is aiming to launch up to 30 drugs in the US market in the current fiscal, whereas it has been awaiting approval of around 160 products from the US Food and Drug Administration (USFDA).

Vinita Gupta, Lupin Group President and CEO has said that “We are looking at roughly around 25 to 30 launches, 15 out of Somerset (Gavis earlier which was acquired by Lupin) and another 15 out of India.

She further further said that majority of the filings out of the company’s sites in India are from Pithampur (Indore) and roughly 30 percent from Goa.

Read EquityPandit’s Technical Analysis on Nifty Pharma